| Workshop 7 (JSH・JSGE・JSGS) |
| Thu. November 1st 9:40 - 12:00 Room 5: Portopia Hotel South Wing Ohwada A |
The role of CLEC18 in clinical manifestation of HCC and its related interferon stimulated pathway
|
|||
| Tsung-Yu Tsai1, Shie-Liang Hsieh2, Cheng-Yuan Peng1 | |||
| 1China Medical University Hospital, 2Genomics Research Center, Academia Sinica | |||
|
|||
|
|||
| Background and aim: C-type lectin 18 (CLEC18) is a novel secretory C-type lectin which is highly expressed in liver. In our previous study, baseline plasma CLEC18 was down-regulated in chronic hepatitis B (CHB) infected patients and hepatocellular carcinoma (HCC). Besides interferon stimulated gene (ISG) such as retinoic acid-inducible gene-I (RIG-I) was also known down-regulating in HCC (Cancer Cell. 2014 Jan13;25(1):49-63). Although the correlation of CLEC18 with ISG and clinical manifestation in HCC was not understood, we aim to investigate it. Methods: Tissue of HCC’s tumor part and its paired non-tumor part for 80 of HBV infected patients was enrolled from Taiwan Liver Cancer Network. The CLEC18, RIG-I and TRAIL level of these tissues was measured by quantitative real time PCR assay. Results: CLEC18 correlates with RIG-I in HCC tumor part and both RIG-I with its downstream tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in its paired non-tumor part. Besides, CLEC18 and TRAIL expression was down-regulated in HBV infected HCC tissue compared to those paired non-tumor tissue. Higher CLEC18 expression in tumor part had higher possibility of portal vein thrombosis (Odds ratio: 4.43). Conclusions: In HBV infected HCC, CLEC18 expression was down-regulated and correlate to RIG-I mediated interferon stimulating pathway. Increased CLEC18 level in HCC tumor showed higher risk of portal vein thrombosis. Monitoring CLEC18 level in HCC is important. |
|||
|
Index Term 1: C-type lectin 18 Index Term 2: Hepatocellular carcinoma |
|||
| Page Top | |||